US › Healthcare

Relay Therapeutics Inc (RLAY)

US · Healthcare · Biotechnology

$19.54+4.05%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.0M
Revenue YoY
-60.9%
Net profit
$-73.3M
Profit YoY
+4.9%
EPS
$-0.41
EPS estimate
$-0.36
Net margin
-2,443.0%

EPS came in at -0.41 against a street estimate of -0.36 — a miss of 13.9%.

Key statistics

Market cap
$4.09B
Forward P/E
0.0
P/B
6.38
Book value
$3.39
EPS (TTM)
$-1.56
52-week high
$20.79
52-week low
$3.02
50-day MA
$17.01
200-day MA
$11.35
Beta
1.70

Analyst view

Analysts rate Relay Therapeutics Inc a buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $26.08.

Shareholding

Insiders
1.35%
Institutions
89.24%

Largest institutional holders

FundStake
SB INVESTMENT ADVISERS (UK) LTD12.80%
COMMODORE CAPITAL LP7.80%
Casdin Capital, LLC6.62%
BlackRock Inc5.95%
Perceptive Advisors LLC4.47%
Bellevue Group AG3.58%
Vanguard Capital Management, LLC3.39%
State Street Corp2.86%

Recent filings & reports

DocumentDate
Charter / bylaws change · Q2 20262026-06-09
Material agreement · Q2 20262026-05-21
Reg FD disclosure · Q2 20262026-05-19
Quarterly report · Q1 20262026-05-05
Results announced · Q2 20262026-05-05
Proxy statement · Q2 20262026-04-28
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Relay Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.